BioSpace News Archive

Xeris Biopharma Holdings, Inc. today announced financial results for the third quarter and first nine months ended September 30, 2021, and recent highlights, including the completion of the Strongbridge Biopharma plc acquisition on October 5, 2021.

NeoGenomics, Inc. has appointed Dave Daly to serve on its Board of Directors. Dave Daly joined our Board of Directors effective November 10, 2021.

4E Therapeutics, Inc. announced that it has been awarded a $5.5 million Phase 2 National Institutes of Health (NIH) Small Business Innovation Research (SBIR) UG3 grant as part of the NIH Helping to End Addiction Long-Term (HEAL) Initiative.

Greenwich LifeSciences, Inc. today provides an update on the upcoming Phase III clinical trial FLAMINGO-01.

Ikena Oncology, Inc., a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, announced financial results for the quarter ended September 30, 2021.

Acasti Pharma Inc., provided a business update and announced its operating and financial results for the second quarter of fiscal 2022 ended September 30, 2021.

PolyPid Ltd., a phase 3 biopharmaceutical company focusing on developing targeted, locally administered, and prolonged-release therapeutics to improve surgical outcomes, provided a corporate update and reported financial results for the three and nine months ended September 30, 2021.

Prelude Corporation (PreludeDx™), announced today that the American Medical Association (AMA) has issued a new, dedicated Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) code for DCISionRT®, the only test available to predict personalized recurrence risk and radiation therapy benefit for patients with ductal carcinoma in situ (DCIS).

Sotera Health Company, a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced financial results for the third quarter and first nine months of 2021.

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), today announced a poster presentation at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), being held virtually November 12-15, 2021.